Lv4
450 积分 2023-10-10 加入
The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant
17小时前
已完结
Second primary malignancies in multiple myeloma: A review
1个月前
已完结
The association between renal cell carcinoma and multiple myeloma: insights from population‐based data
1个月前
已完结
Borrelia and subsequent risk of solid tumors and hematologic malignancies in Sweden
1个月前
已完结
Polatuzumab vedotin–based salvage immunochemotherapy as third-line or beyond treatment for patients with diffuse large B-cell lymphoma: a real-world experience
1个月前
已完结
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study
1个月前
已完结
Mosunetuzumab plus Pola-CHP compared with Pola-R-CHP in previously untreated DLBCL: final results from a Phase II study
1个月前
已关闭
Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
1个月前
已关闭
POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1个月前
已完结
POLARGO: Randomized Phase III Study of Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
1个月前
已关闭
皖公网安备34019202002308
